YH010_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._pdl1,il12,bi-specific antibody,biocytogen

YH010 is a potentially first-in-class fully human PD-L1 x IL12 bispecific antibody for the treatment of solid tumors. YH010 simultaneously activates the IL12 signaling pathway while inhibiting PD-L1 binding to PD-1. YH010 also has the potential to further enhance the specific killing activity of T cells by tethering IL12R positive T cells with PD-L1 positive tumor cells.